Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

December 20, 2023

https://www.globenewswire.com/news-release/2023/12/20/2799211/15459/en/Myriad-Genetics-Establishes-Comprehensive-Pan-Cancer-Research-Platform-to-Advance-Patient-Care.html

SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry™ (MCRR). Formerly known as the Precise Treatment Registry, the MCRR includes new data across germline and tumor testing results from Myriad’s cancer products on more than one million patients. The latest enhancements make the MCRR one of the largest pan-cancer registries freely available for research use and supports transparent clinical data sharing to advance the field.

Read more at globenewswire.com

Related news for (MYGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.